The genomic and transcriptomic landscape of anaplastic thyroid cancer: implications for therapy. Issue 1 (December 2015)

• Record Type: Journal Article
• Authors: Kasaian, Katayoon; Wiseman, Sam; Walker, Blair; Schein, Jacqueline; Zhao, Yongjun; Hirst, Martin; Moore, Richard; Mungall, Andrew; Marra, Marco; Jones, Steven
• Is Part Of: BMC cancer. Volume 15:Issue 1(2015)
• Page Start: 1
• Page End: 11
• Publication Date: 2015-12
• Subjects: Anaplastic thyroid carcinoma -- cell line -- whole genome and transcriptome sequencing -- FGFR2-OGDH fusion -- SS18-SLC5A11 fusion -- MKRN1-BRAF fusion -- epigenetic alterations -- mTOR signaling pathway -- therapy targets; Cancer -- Periodicals; 616.994005
• DOI: 10.1186/s12885-015-1955-9
• Languages: English
• ISSNs: 1471-2407

Abstract

Abstract Background Anaplastic thyroid carcinoma is the most undifferentiated form of thyroid cancer and one of the deadliest of all adult solid malignancies. Here we report the first genomic and transcriptomic profile of anaplastic thyroid cancer including those of several unique cell lines and outline novel potential drivers of malignancy and targets of therapy. Methods We describe whole genomic and transcriptomic profiles of 1 primary anaplastic thyroid tumor and 3 authenticated cell lines. Those profiles augmented by the transcriptomes of 4 additional and unique cell lines were compared to 58 pairs of papillary thyroid carcinoma and matched normal tissue transcriptomes from The Cancer Genome Atlas study. Results The most prevalent mutations were those ofTP53 andBRAF ; repeated alterations of the epigenetic machinery such as frame-shift deletions ofHDAC10 andEP300, loss ofSMARCA2 and fusions ofMECP2, BCL11A andSS18 were observed. Sequence data displayed aneuploidy and large regions of copy loss and gain in all genomes. Common regions of gain were however evident encompassing chromosomes 5p and 20q. We found novel anaplastic gene fusions includingMKRN1-BRAF, FGFR2-OGDH andSS18-SLC5A11, all expressed in-frame fusions involving a known proto-oncogene. Comparison of the anaplastic thyroid cancer expression datasets with the papillary thyroid cancer and normal thyroid tissue transcriptomes suggested several known drug targets such asFGFRs, VEGFRs, KIT andRET to have lower expression levels in anaplastic specimens compared with both papillary thyroid cancers and normal tissues, confirming the observed lack of response to therapies targeting these pathways. Further integrative data analysis identified the mTOR signaling pathway as a potential therapeutic target in this disease. Conclusions Anaplastic thyroid carcinoma possessed heterogeneous and unique profiles revealing the significance of detailed molecular profiling of individual tumors and the treatment of each as a unique entity; the cell line sequence data promises to facilitate the more accurate and intentional drug screening studies for anaplastic thyroid cancer.